Search

Displaying results 4501 - 4510 of 7063 in total
  1. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  2. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  3. Drug

    9,10-Deepithio-9,10-Didehydroacanthifolicin

    go.drugbank.com/drugs/DB02169
    Experimental

    A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)

  4. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Human umbilical cord is a rich source of hematopoietic stem cells and progenitor cells that are capable of proliferation _in vitro_. … After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings.

  5. Drug

    CHF5633

    go.drugbank.com/drugs/DB18696
    Investigational

    CHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a

    Synonyms: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
  6. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  7. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment

  8. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively

  9. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. … It was granted approval by FDA in August 2017 under the market name Kymriah.

  10. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults. … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.